Integrated analysis of patient networks and plasmid genomes

1 2

reveals a regional, multi-species outbreak of carbapenemase-

3 producing Enterobacterales carrying both *bla*_{IMP} and *mcr-9* genes

Yu Wan^{1*}, Ashleigh C. Myall^{1,3*}, Adhiratha Boonyasiri^{1,2*}, Frances Bolt^{1,4,5}, Alice Ledda^{6,7}, 4 Siddharth Mookerjee⁴, Andrea Y. Weiße^{8,9}, Maria Getino¹, Jane F. Turton⁷, Hala Abbas^{1,10}, 5 Ruta Prakapaite¹¹, Akshay Sabnis¹¹, Alireza Abdolrasoulia⁴, Kenny Malpartida-Cardenas^{1,12}, 6 Luca Miglietta^{1,12}, Hugo Donaldson¹⁰, Mark Gilchrist^{1,4}, Katie L. Hopkins^{1,7}, Matthew J 7 Ellington^{1,13}, Jonathan A. Otter¹, Gerald Larrouy-Maumus^{1,14}, Andrew M. Edwards¹¹, Jesus 8 Rodriguez-Manzano^{1,5,12}, Xavier Didelot¹⁵, Mauricio Barahona³, Alison H. Holmes^{1,4,5}, Elita 9 Jauneikaite^{1,6#}, and Frances Davies^{1,4,10#} 10 11 12 NIHR Health Protection Research Unit in Healthcare Associated Infections and 1. 13 Antimicrobial Resistance, Department of Infectious Disease, Imperial College London, 14 London, United Kingdom. 15 Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 2. 16 Department of Mathematics, Imperial College London, London, United Kingdom 3. 17 Imperial College Healthcare NHS Trust, London, United Kingdom 4. 18 Centre for Antimicrobial Optimisation, Hammersmith Hospital, Imperial College 5. 19 London, Du Cane Road, London, United Kingdom 20 6. Department of Infectious Disease Epidemiology, School of Public Health, Imperial 21 College London, London, United Kingdom 22 7. HCAI, Fungal, AMR, AMU & Sepsis Division, UK Health Security Agency, London, 23 United Kingdom 24 8. School of Biological Sciences, University of Edinburgh, Scotland, United Kingdom 25 School of Informatics, University of Edinburgh, Scotland, United Kingdom 9. 26 10. Department of Microbiology, North West London Pathology, London, United Kingdom 27 11. MRC Centre for Molecular Bacteriology and Infection, Department of Infectious 28 Disease, Faculty of Medicine, Imperial College London, London, United Kingdom 29 12. Centre for Bio-Inspired Technology, Department of Electrical and Electronic 30 Engineering, Faculty of Engineering, Imperial College London, United Kingdom 31 13. Reference Services Division, UK Health Security Agency, London, United Kingdom

- 32 14. MRC Centre for Molecular Bacteriology and Infection, Department of Life Sciences,
- 33Faculty of Natural Sciences, Imperial College London, London, United Kingdom
- 34 15. School of Life Sciences and Department of Statistics, University of Warwick, United
 35 Kingdom
- 36 * These authors contributed equally; # these senior authors contributed equally.
- Keywords: Carbapenem-resistant Enterobacterales, IMP carbapenemase, horizontal gene
 transfer, spatiotemporal network, patient pathways
- 39 **Running title:** Multispecies regional IMP Plasmid CPE outbreak

40 Summary: This study describes an investigation, using integrated pathway networks and 41 genomics methods, of the emergence of IMP-encoding CPE amongst diverse 42 Enterobacterales species between 2016 and 2019 in patients across a London regional 43 hospital network, which was missed on routine investigations.

44 Corresponding author:

- 45 Frances Davies, MD, PhD,
- 46 Email: <u>Frances.Davies1@nhs.net</u>, <u>f.davies@imperial.ac.uk</u>
- 47 Telephone: +44 7879 454954

48 Alternative corresponding author:

- 49 Elita Jauneikaite, PhD
- 50 Email: <u>e.jauneikaite@imperial.ac.uk</u>
- 51 Telephone: +44 7763 294900
- 52

53 Abstract

54 Background

55 Carbapenemase-producing Enterobacterales (CPE) are challenging in the healthcare setting, 56 with resistance to multiple classes of antibiotics and a high associated mortality. The 57 incidence of CPE is rising globally, despite enhanced awareness and control efforts. This 58 study describes an investigation of the emergence of IMP-encoding CPE amongst diverse 59 Enterobacterales species between 2016 and 2019 in patients across a London regional 60 hospital network.

61 Methods

We carried out a network analysis of patient pathways, using electronic health records, to identify contacts between IMP-encoding CPE positive patients. Genomes of IMP-encoding CPE isolates were analysed and overlayed with patient contacts to imply potential transmission events.

66 **Results**

67 Genomic analysis of 84 Enterobacterales isolates revealed diverse species (predominantly 68 *Klebsiella* spp, *Enterobacter* spp, *E. coli*), of which 86% (72/84) harboured an IncHI2 69 plasmid, which carried both *bla*_{IMP} and the mobile colistin resistance gene *mcr-9* (68/72). 70 Phylogenetic analysis of IncHI2 plasmids identified three lineages which showed significant 71 association with patient contact and movements between four hospital sites and across 72 medical specialities, which had been missed on initial investigations.

73 Conclusions

Combined, our patient network and plasmid analyses demonstrate an interspecies, plasmidmediated outbreak of bla_{IMP} CPE, which remained unidentified during standard microbiology and infection control investigations. With DNA sequencing technologies and multi-modal data incorporation, the outbreak investigation approach proposed here provides a framework for real-time identification of key factors causing pathogen spread. Analysing outbreaks at the plasmid level reveals that resistance may be wider spread than suspected, allowing more targeted interventions to stop the transmission of resistance within hospital networks.

81

82 Introduction

83 Infections by carbapenemase-producing Enterobacterales (CPE) pose a substantial clinical, 84 operational, and financial challenge [1]. These organisms are associated with high morbidity 85 and mortality, and therapeutic options are severely restricted [2]. Carbapenemase genes are 86 frequently carried on plasmids, which can easily transfer between bacterial species [3]. CPE 87 outbreaks involving different bacterial species are often unrecognised, as many plasmids are 88 variable in their gene content and have a broad host range [4]. Outbreaks of Enterobacterales 89 carrying Imipenemase (IMP) gene bla_{IMP-1} are mostly sporadic and often localised to specific 90 geographical locations [5, 6]. IMP genes are rarely isolated in the UK, however, the number 91 of IMP encoding Enterobacterales species isolates referred to UK Health Security Agency 92 has been increasing [7].

93

Colistin and polymyxin B remain the last-line therapeutic agents for CPE in most countries, partly due to lack of access to newer agents; yet colistin resistance is increasing globally. Ten mobile colistin resistance genes (mcr-1 - mcr-10) have been described to date, presenting a substantial global healthcare challenge [8, 9]. Although mcr genes are typically associated with phenotypic polymyxin resistance, mcr-9 does not appear to confer direct colistin resistance [10, 11] and is widespread in a wide range of bacterial species from human, animal and environments [11-14].

101

102 Person-to-person contact is a route of transmission for many infectious diseases. 103 Consequently, understanding the patterns of these contacts, especially in healthcare settings, 104 can offer detailed insight for targeted interventions [15]. However, such patient contacts 105 become increasingly complex when incorporating multi-layers of data. Network models 106 provide flexible tool to capture complex interactions (contact patterns) and, offer robust and 107 reproducible methodology that has become widespread across disciplines [16, 17], 108 incorporating both person-to-person transmission through contact networks [18] and spatial 109 spread through networks representing physical locations [19]. So far, few studies utilised 110 network models of patient contacts in combination with detailed bacterial genomic analysis 111 and demonstrated such approach advantages through increasing the detail in outbreak 112 characterisation [20, 21].

113

- 114 Here, we combine plasmid phylogenomic analysis with patient-contact networks to discover
- 115 the spread of *bla*_{IMP} and *mcr-9* genes among bacterial species and patients in a large hospital
- 116 network in London, UK over three years, providing valuable insights for the management of
- 117 CPE in hospital settings.

118 Materials and Methods

119 Clinical setting

120 This study was carried out using data from a regional network of London hospitals, 121 comprising seven hospital sites with a total of 2000 inpatient beds, with managerial 122 responsibility assigned to two National Health Service Trusts, and frequent transfers between 123 Trusts and sites for specialist care. Cases were identified from one of these trusts (comprising 124 five hospitals), with microbiology and pathway data for those cases was identified through a 125 shared centralised microbiology laboratory and Electronic Health Records (EHR) system 126 (Cerner, UK). Since June 2015, an enhanced routine CPE screening programme has been 127 implemented in this trust [22]. When a new case of CPE was identified, the patient was 128 isolated in a single room with contact precautions, the bed space and bathroom were 129 terminally enhanced cleaned, and any contacts were re-screened for CPE.

130 Isolate collection

131 CPE isolates were collected from cases identified through rectal screens or clinical sampling 132 between June 2016 and November 2019. Bacterial species were determined using Biotyper 133 MALDI-TOF mass spectrometry (Bruker Daltonics, Germany). One isolate per species was 134 collected from each patient. Susceptibility to 21 antimicrobials was tested using EUCAST 135 disc-diffusion method, and colistin MICs were retrospectively determined using 136 MICRONAUT broth microdilution (BioConnections, UK) for all viable CPE isolates 137 carrying bla_{IMP} genes (hereafter, bla_{IMP} CPE) [23]. Further phenotypic and molecular 138 characterisation of CPE isolates were performed as described in Supplementary Methods.

139 Whole-genome sequencing (WGS)

Isolates of *bla*_{IMP}CPE were grown aerobically on Columbia Blood Agar (Oxoid Ltd, UK) at
37°C. Genomic DNA was extracted from overnight cultures using GenElute Bacterial
Genomic DNA Kits (Sigma-Aldrich, USA). Multiplexed DNA libraries were generated with

- 143 Nextera XT (Illumina, USA) and sequenced under a 150-bp paired-end layout for a minimum
- 144 of 100-fold coverage on Illumina HiSeq 4000 systems (Illumina, USA).

145 **Phylogenomic analysis**

146 Quality control of sequencing reads, *de novo* genome assembly, and genetic characterisation 147 of isolates are described in Supplementary Methods. A neighbouring-joining tree of CPE 148 genomes was generated from pairwise average nucleotide distances using FastANI v1.33 149 [24]. Plasmid sequences were reconstructed from genome assemblies using MOB-suite 150 v3.1.0 [25]. Reconstructed sequences of IncHI2 plasmids were aligned against IncHI2 151 plasmid pKA_P10 (GenBank accession: CP044215.1) using Snippy 152 (github.com/tseemann/snippy) to identify genetic variation. A recombination-corrected 153 maximum-likelihood (ML) tree of IncHI2 plasmids was reconstructed from the sequence 154 alignment using IQ-Tree v2.0.3 [26] as implemented in Gubbins v3.2.1 [27]. The date of the 155 most-recent common ancestor of IncHI2 plasmids was estimated using Bactdating v.1.1.1 156 [28].

157 Network analysis

158 To reveal potential transmission structure, a patient contact network was reconstructed from 159 patients' movement history (ward locations and time) extracted from EHR data of *bla*_{IMP}CPE 160 cases. A contact was defined as an event when two patients were present on the same ward on 161 the same day. Time-aggregated patient contacts were subsequently clustered to reveal groups 162 of patients linked together using the Walktrap community detection algorithm [29]. Contacts 163 were weighted by the time spent together, and a temporal analysis of patient interactions was 164 performed to assess patient roles and positions in transmission. A spatial network of 165 ward/hospital distributions was generated, allowing calculation of in-hospital infectious 166 periods — days spent on the ward prior to implementation of infection prevention and control 167 (IPC) measures, a network structure to determine ward/hospital spread, and a list of highly 168 visited wards according to plasmid genetic clusters.

169

To investigate if the identified lineages of IncHI2 plasmids represented the transmission of *bla*_{IMP}CPE, a Kendall's rank correlation coefficient was calculated from pairwise phylogenetic distances between IncHI2 plasmids (extracted from the plasmid ML tree) and shortest-path distances between patients (from whom isolates carrying these plasmids were collected) in the contact network (Supplementary Methods).

175 Data availability

176 Illumina reads and draft genome assemblies of 84 bla_{IMP}CPE isolates were deposited in

177 European Nucleotide Archive under BioProject PRJEB38818. See Supplementary Table 1 for

178 sample information.

179 **Ethics**

180 This study was carried out in accordance with ethics reference 21/LO/0170 (279677),

181 protocol 21HH6538 Investigation of epidemiological and pathogenic factors associated with

182 infectious diseases.

183 **Results**

184 Incidence of *bla*_{IMP}CPE

185 Following the introduction of the enhanced CPE screening programme, *bla*_{IMP}CPE was first 186 observed in two Trusts' hospitals in June 2016 through routine rectal screening. From 187 November 2016, an increasing number of $bla_{\rm IMP}$ CPE isolates was identified across 188 Enterobacterales species (Figure 1A). The highest incidence of bla_{IMP}CPE cases occurred 189 between January and July 2019 (Figure 1B). Altogether, bla_{IMP}CPE isolates were recovered 190 from screening or clinical samples from 116 patients admitted to these five hospitals by the 191 end of November 2019, when new cases rapidly dropped, and subsequent cases were 192 sporadic and infrequent. No ward or service was identified as a potential focus for cross 193 transmission, and no enhanced IPC measures were taken. Only two clusters of cases (5/116 194 cases) fitted the conventional outbreak definition that ≥ 2 cases of the same bacterial species 195 with the same resistance mechanism overlapping in time and space. Pulsed-field gel 196 electrophoresis typing of CPE isolates showed similar profiles, suggesting within-hospital 197 transmission. Furthermore, the daily number of occupied beds revealed a continuous burden 198 of patients colonised with *bla*_{IMP}CPE (Figure 1C). This burden was particularly evident for 199 patients colonised by *Enterobacter*, with 424 total bed days in the peak month (March 2019) 200 across the hospital network.



202 Figure 1. Characteristics of confirmed blamPCPE cases and CPE species. Colours in each panel 203 indicate the genus of CPE. (A) Total number of bed days when inpatients (rows labelled by isolate 204 identifier) were present in a hospital ward before confirmation of bla_{IMP}CPE colonisation/infection and 205 related IPC measures (in-hospital infectious period). Additionally, patients with known carriage of 206 bla_{MP}CPE but without sequenced isolates are shown as unlabelled rows. Patients with two species of 207 CPE isolates (IMP22/24, IMP25/33, IMP96/97, IMP100/101) are on adjacent rows. (B) Monthly total 208 number of confirmed bla_{MP}CPE isolates from patients during the study period 2016–2019. (C) Weekly 209 cumulative number of occupied beds in-hospital during the infectious periods.

210 Contact network of *bla*_{IMP}CPE-positive cases

A detailed patient contact network for 116 $bla_{IMP}CPE$ cases confirmed that 77/116 (66%) cases were in contact with at least one other $bla_{IMP}CPE$ case (ranged from one to 10 with a median of two cases; Figure 2 and Supplementary Table 2), creating 96 patient-contact pairs (Supplementary Table 3).

215

201

Across all contact pairs of *bla*_{IMP}CPE cases, detected bacterial species differed in 59% (57/96) of patient pairs and therefore, were excluded from the conventional same-species definition of an outbreak when initially reviewed. The network of patient contacts split patients into 12 separate clusters, with interactions occurring across different hospitals, as patients were transferred between wards and hospital sites (Figure 2). The largest contact cluster (Cluster 1) contained 45 patients and was partitioned into a further seven sub-clusters 222 (labelled 1.1 to 1.7) that comprised 13, 12, 2, 6, 5, 5, and 2 patients, respectively (Figure 2). 223 The analysis of contacts at regional, hospital, and ward levels suggested involvement of 224 different $bla_{IMP}CPE$ species in patient-to-patient transmission events and prompted 225 phylogenomic analysis of available $bla_{IMP}CPE$ isolates.



227 Figure 2. Contact network of blampCPE cases. Each node of the network represents a case, 228 coloured according to CPE species (split colours indicates two species), and each edge represents a 229 contact between two patients, *i.e.*, patients present on the same ward on the same day based on their 230 electronic health records. This network contains 12 distinct major clusters (each shaded in light grey, 231 with sub-clusters 1.1-1.7 shaded in a different colour) based on disconnected components of 232 contacts. Cluster 1, the largest cluster consisting of 45 cases, was further partitioned into seven 233 subclusters using community detection, with edges weighted by the duration of contact 234 (Supplementary methods - Network community detection). Six patient contacts re-occurred over 235 different wards, indicated by additional edges connecting the same patients.

236 Genomic and phenotypic characterisation of *bla*_{IMP}CPE isolates

226

A total of 84 bla_{IMP} CPE isolates (collected from 82/116 cases) were available for wholegenome sequencing (Supplementary Table 1). These isolates belonged to 15 species and were dominated by those of the *Enterobacter cloacae* complex (n = 51), followed by *Klebsiella* spp. (n = 21) and *E. coli* (n = 8) (Figure 3). Four cases (Cases 20, 24, 90, 97) were colonised by two *bla*_{IMP}CPE species (Supplementary Table 2).



242

Figure 3. A neighbour-joining tree of 84 *bla*_{IMP}CPE isolates. This tree was constructed from average nucleotide distances between genomic sequences and was midpoint rooted. The colour at the end of each branch indicates the bacterial species identity for that isolate. The rings are as follows: the innermost ring indicates the type of plasmid detected; the second ring indicates the allelic variant of the *bla*IMP gene detected, the third ring indicates the presence or absence of gene *mcr-9* and the outermost ring indicates hospitals. The scale bar indicates the pairwise average nucleotide divergence (%).

250 Each of these 84 isolates carried either bla_{IMP-70} (n = 74) and bla_{IMP-4} (n = 10). IncHI2 251 plasmids (targeted by both probes for IncHI2 and IncHI2A replicons in the PlasmidFinder 252 database) were detected in 72 isolates from 72 cases, and IncN3 plasmids were detected in 10 253 isolates from 10 cases (Figure 3). Only IMP79 harboured both IncHI2 (without any bla_{IMP} 254 genes) and IncN3 (carried bla_{IMP-70}) plasmids. Seventy of the 72 IncHI2 plasmids carried 255 either bla_{IMP-70} (n = 61) or bla_{IMP-4} (n = 9), and all IncN3 plasmids carried bla_{IMP-70} 256 (Supplementary Tables 4 and 5). Four isolates carried bla_{IMP} genes that were not found in 257 either IncHI2 or IncN3 plasmids: one *bla*_{IMP-4} was integrated into the chromosome of IMP66, 258 and *bla*_{IMP-70} was carried by an IncFIB/FII plasmid in IMP83 and by IncHI1 plasmids in IMP47 and IMP76. All bla_{IMP} CPE isolates carried multiple β -lactam resistance genes and other antimicrobial resistance genes, yet only IMP89 had an additional carbapenemresistance gene bla_{OXA-48} (Supplementary Table 1).

262

263 Gene mcr-9 was detected in 69/84 (82%) isolates, with mcr-9 identified present on 68 IncHI2 264 plasmids, one outlier IncHI2 plasmid (32% coverage of the reference plasmid pKA P10 by 265 sequencing reads), and none of the IncN3 plasmids (Supplementary Tables 4 and 5). The 266 mcr-9 LAMP assay showed 100% concordance with the WGS results (Supplemental Table 267 1). MALDIxin did not detect any Lipid A modifications attributable to the *mcr*-9 gene in this 268 study. Altogether, 12 isolates (all *Enterobacter*) were resistant to colistin (MICs ranged 269 between 4 and $>64 \mu g/mL$), including five isolates that demonstrated a skipped-well 270 phenomenon suggestive of colistin heteroresistance (Supplementary Table 1), a phenomenon 271 previously reported [30].

272 Genetic relatedness between plasmids

273 All 72 reconstructed IncHI2 plasmids belonged to the same plasmid taxonomic unit PTU-274 HI2, and representative sequences are compared in Supplementary Figure 1. Altogether, 144 275 single-nucleotide polymorphic sites were identified in the alignment of these 72 plasmids 276 after correcting for recombination events, with pairwise phylogenetic distances (sums of 277 branch lengths in the plasmid tree) ranged from zero to 115 single-nucleotide polymorphisms 278 (SNPs). Specifically, of the 72 plasmids analysed in the tree, 43 (60%) differed by \leq 3 SNPs, 279 and 55 (76%) differed by \leq 5 SNPs. This high degree of similarity between IncHI2 plasmids 280 suggests potential horizontal gene transfer or transfer of full plasmids between different 281 bacterial species. In the case of IncHI2 plasmids present in the same species, a comparison 282 between the plasmid and *E. hormaechei* (the most common species in our data) phylogenetic 283 trees showed likely vertical transmission events as closely related isolates had highly similar 284 plasmids (Supplementary Figure 2). By contrast, reconstructed IncN3 plasmids showed large 285 structural variation in the plasmids (Supplementary Figure 3) and no reliable phylogenetic 286 tree could be reconstructed.

287

The phylogenetic tree of IncHI2 plasmids indicated three major lineages A, B, and C (Figure 4 and Supplementary Table 6). The estimated date of the most recent common ancestor of the 72 IncHI2 plasmids was 1765 with a large 95% confidence interval of 1536–1895 despite a

- 291 desirable convergence of the optimised molecular clock model (Supplementary Figure 4),
- suggesting a lack of temporal signals in reconstructed IncHI2 plasmids.
- 293



294

Figure 4. Recombination-corrected maximum-likelihood tree of 72 reconstructed IncHI2 295 296 plasmids from bla_{IMP}CPE isolates and the reference plasmid pKA_P10. Coloured branches and 297 shades represent plasmid lineages A, B, and C, with bootstrap values of lineage roots noted. The 298 heat map shows presence-absence of antimicrobial resistance genes identified in plasmids, and the 299 bar plot shows relative lengths (%) of the reconstructed plasmids compared to that of the reference 300 plasmid pKA_P10. This tree is rooted on the outgroup pIMP79, which was deemed an outgroup 301 according to its phylogenetic distances to other IncHI2 plasmids and by the BactDating root-to-tip 302 analysis (Supplementary Figure 4).

303 Comparison between plasmid lineages and patient clusters

304 Pairwise phylogenetic distances between IncHI2 plasmids and shortest-path distances 305 between patients showed a significant correlation (Kendall's correlation coefficient = 0.19, pvalue = 3×10^{-7}) (Figure 5A), despite WGS data being unavailable for isolates from 24 cases. 306 307 This correlation between plasmid population structure and patient contact network suggests 308 that ward contacts mediated transmission of these plasmids between patients or from 309 unidentified common sources. When case contacts were weighted by patients' time spent 310 together, the *bla*_{IMP}CPE outbreak was heavily weighted towards Hospital 3, the specialist 311 referral centre for cardiology, renal, haematology and hepatobiliary services, with 72.1% of 312 contacts occurring there.



314 Figure 5. Epidemiology of blampCPE genetic clusters across patient interactions and 315 movement. (A) Patient contact network overlaid with plasmid lineages A, B, and C. Each node 316 represents a patient, edges represent recorded ward contacts between confirmed *bla*_{MP}CPE cases. 317 The edges are coloured according to the hospital site and the width of the edge is proportional to the 318 duration of the contact. Nodes are coloured according to the three lineages of IncHI2 plasmids, and 319 patients with isolates that did not have any IncHI2 plasmids detected are coloured in white. Node 320 labels indicate IncHI2 plasmid names in Supplementary Table 4 (e.g., '88' indicates plasmid pIMP88, 321 and '100/101' indicates plasmids pIMP100 and pIMP101 from the same case). The presence/absence 322 of IncN3 plasmids in bla_{IMP}CPE isolates is denoted by node shapes. (B) Hospital-level patient 323 movements. The movement of patients carrying *bla*_{MP}CPE are indicated by arrows between hospitals. 324 Repeated transfers of patients between wards are aggregated into edges with proportionally greater edge widths (grouped by sequenced and non-sequenced). Edges with sequencing data are colouredaccording to IncHI2 plasmid lineages.

This was confirmed by the analysis of the spatial distribution and movement of cases colonised with $bla_{IMP}CPE$ carrying IncHI2 plasmids (Figure 5B). The largest lineage (Lineage C) was found the most prevalent on wards within Hospital 3 (1919 patient beddays) and followed bidirectional transfer pathways to and from Hospitals 1, 2 and 4, which all have large general medical and surgical admissions areas. Lineage A followed a similar pattern of distribution, though with less transfers identified to Hospital 2, which may have been due to unidentified or missing case data.

334

The association between plasmid lineage clusters and ward/specialties over the study period showed the most common associations across critical care and renal services (Supplementary Table 7). The only exception was general internal medicine and general surgery predominated in plasmid Lineage A at Hospital 4, which has more general wards and less specialist services than the other hospital sites in the network. Despite the predominance of cases being identified in specialties with high risk for invasive disease, only four clinical infections were identified during the study, and no blood stream infections.

342 **Discussion**

343 Following the detection of a new mechanism of resistance, investigation of its origin and 344 mode of transmission is challenging, especially in healthcare settings where investigations 345 usually focus on single species transmissions. With confounding factors such as multiple 346 bacterial species and spread over different hospital locations, new methods to investigate 347 potential outbreaks are much needed. The incorporation of plasmid genomics and patient 348 networks into our analysis changed the way the emergence of $bla_{\rm IMP}$ CPE was visualised and 349 produced a clearer understanding of the cumulative burden of cases, high-risk ward locations 350 and pathways for potential cross transmission in our regional healthcare system. As patients 351 were found to follow common routes, with regular re-encounters, this information can 352 provide dynamic risk assessments to be introduced along those pathways, to prevent future 353 cross transmission events of any healthcare-associated pathogen from occurring [31]. 354 Detailed genomic analysis of plasmids enhanced our understanding of the relatedness of 355 different patient isolates to the network analysis, and similarity to those plasmids identified in 356 other hospitals in the UK [32]. It moreover revealed concerning information about 357 unsuspected resistance mechanisms, with potential for antibiotic treatment failures that were 358 missed on conventional laboratory susceptibility testing. In this study, we characterized 359 IncHI2 plasmids as the main vehicle in horizontal transfer of the metallo- β -lactamase gene 360 *bla*_{IMP}. IncHI2 plasmids are common, large plasmids with a wide host range, that have been 361 reported globally [14]. Although in our study we detected mcr-9 in 81% of the isolates 362 tested, we did not find evidence of phenotypic expression of this gene, in line with previous 363 observations [11, 33]. We identified the predominant IncHI2 plasmid in multiple different 364 bacterial species across linked patients, highlighting the need for integration of genomics into 365 routine clinical practice. Although this study focussed on the emergence of the $bla_{\rm IMP}$ 366 carbapenemase gene in our hospital network, it supports the concept that plasmid analysis 367 across different resistance mechanisms as well as among different species should be the 368 standard for investigations in the future. Network analyses and cumulative burden analyses 369 can help identify targets for WGS, particularly where resources are not sufficient to support 370 WGS of all new CPE cases identified. The small number of clinical infections from this 371 outbreak in comparison to other CPE outbreaks from our hospital network [34] and other 372 reports of *bla*_{IMP} CPE [11, 14] is noteworthy, and poses questions about the wider importance 373 of this plasmid and the resistance mechanisms revealed in this study. This observation 374 reinforces the argument that screening for silent carriage of CPE in hospitals is key to 375 preventing spread [35-37], and cautious antimicrobial stewardship is essential to prevent 376 expression of hidden resistance mechanisms [38].

377

378 We acknowledge some limitations of our study. Firstly, we did not have long read sequences 379 for plasmids analysed as part of this study. As a result, our plasmid tree may omit some 380 similarities and differences between identified IncHI2 plasmids. Secondly, full pathway data 381 across the hospital during the three years of the outbreak was only available for identified 382 positive cases, not for all patients in the hospitals during the study period. It was therefore not 383 possible to fully establish potential missed cases flagging as close contacts but with potential 384 for missed screening or false negative results. Full pathway movement data for all positive 385 cases identified within our hospital network was available, yet neither pathway details nor 386 genomic data were available for other *bla*_{IMP}CPE-positive cases identified in the two other 387 regional hospitals who did not visit our institution, thus reducing the understanding in our 388 analysis. Interactions at other potential hospital locations such as interventional imaging or 389 endoscopy were not examined in this study, nor was environmental sampling performed,

390 which could inform future studies on modes of transmission.

391

392 Nevertheless, this study highlights a previously unidentified extent of transmission and thus 393 provides valuable new insights into the spread of an emerging resistance mechanism. 394 Moreover, our novel multi-layered methodology, incorporating plasmid phylogeny with 395 contact network analysis, provides invaluable tools for outbreak investigation that can be 396 generalised to a wide range of scenarios.

397

398 Acknowledgements

399 We thank the staff of the diagnostic microbiology laboratory of North West London 400 Pathology, for isolate collection and storage. We would also like to acknowledge the support 401 of the Imperial College Healthcare Trust NIHR Biomedical Research Centre (BRC). The 402 Imperial BRC Genomics Facility has provided resources and support that have contributed to 403 the research results reported within this paper. The Imperial BRC Genomics Facility is 404 supported by NIHR funding to the Imperial Biomedical Research Centre. This publication 405 made use of the PubMLST website (https://pubmlst.org/) developed by Keith Jolley (Jolley & 406 Maiden 2010, BMC Bioinformatics, 11:595) and sited at the University of Oxford. The 407 development of that website was funded by the Wellcome Trust.

408

409 Funding

410 This work was supported in part by the faculty of medicine, Siriraj hospital, Mahidol 411 university, Thailand (awarded to AB) and Medical Research Council Clinical Academic 412 Research Fellowship scheme (awarded to FD, grant number MR/T005254/1).

413

414 AM is funded in part by a scholarship from the Medical Research Foundation National PhD 415 Training Programme in Antimicrobial Resistance Research (MRF-145-0004-TPG-AVISO), 416 the EPSRC Centre for Mathematics of Precision Healthcare (EP/N014529/) and through 417 a National Institute for Health Research Senior Research Investigator Award. AM and MB 418 acknowledge funding from EPSRC grant EP/N014529/1 to MB, supporting the EPSRC 419 Centre for Mathematics of Precision Healthcare. AS is funded by a PhD studentship from the 420 Medical Research Council Doctoral Training Award to Imperial College London 421 (MR/N014103/1). AME acknowledges support from the National Institute for Health 422 Research (NIHR) Imperial Biomedical Research Centre (BRC). EJ is an Imperial College 423 Research Fellow, funded by Rosetrees Trust and the Stoneygate Trust (M683). YW is an 424 Institutional Strategic Support Fund Springboard Research Fellow, funded by the Wellcome 425 Trust and Imperial College London. HA was supported by the Imperial Health Charity. XD is 426 supported by the NIHR Health Protection Research Unit in Genomics and Enabling Data. AL 427 acknowledges funding from the National Institute for Health Research Health Protection 428 Research Unit (NIHR HPRU) in Modelling Methodology at Imperial College London (grant 429 HPRU-2012–10080) and the National Institute for Health Research (NIHR) Health Protection 430 Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at 431 University of Oxford (NIHR200915) in partnership with UK Health Security Agency. AH is 432 a National Institute for Health Research (NIHR) Senior Investigator. AH, FD, EJ, AB, YW, 433 ME, MG are affiliated with the National Institute for Health Research Health Protection 434 Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial 435 Resistance at Imperial College London in partnership with the UK Health Security Agency 436 (previously PHE), in collaboration with, Imperial Healthcare Partners, University of 437 Cambridge and University of Warwick. This report is independent research funded by the 438 National Institute for Health Research. The views expressed in this publication are those of 439 the author(s) and not necessarily those of the NHS, the National Institute for Health Research, 440 the Department of Health and Social Care or the UK Health Security Agency.

441

442 **Declarations of Interest**

JT holds some shares in Oxford Nanopore Technologies. All other authors have nothing todeclare.

445

446 Author contributions

- 447 Conceptualization: FD, EJ, AH, MB, FB, XD, ME. Data curation: YW, BA, EJ, AM, FD,
- 448 SM, AW, ME. Formal analysis: AB, AM, YW, MG, FB, FD, EJ, AW, MB, AH, ME.
- 449 Funding acquisition: AB, FD, AH, ME. Investigation: AB, YW, AM, HA, RP, AL, AA, JT,
- 450 LM, KM-C, AS, GL-M, JR-M. Methodology: FD, AM, AW, SM, YW, EJ, BA, XD, MB, JO,
- 451 KH, ME, JT, MG. Project administration: FB, AH, FD, EJ. Resources: FD, AH, AE, HD,
- 452 KH, JT. Supervision: FD, EJ, AH, MB. Validation: KH, JT, ME, HD, AW, SM.
- 453 Visualization: AB, AM, YW, EJ, FD. Writing original draft and further drafts: AB, AM,
- 454 YW, EJ, FD, FB. Writing review & editing: All authors.

455 **References**

- Otter JA, Burgess P, Davies F, et al. Counting the cost of an outbreak of carbapenemase producing Enterobacteriaceae: an economic evaluation from a hospital perspective.
 Clinical microbiology and infection : the official publication of the European Society of
 Clinical Microbiology and Infectious Diseases 2017; 23(3): 188-96.
- Pranita D. Tamma SLA, Robert A. Bonomo, Amy J. Mathers, David van Duin, Cornelius
 J. Clancy. Infectious Diseases Society of America Antimicrobial Resistant Treatment
 Guidance: Gram-Negative Bacterial Infections. Available at: https://www.idsociety.org/practice-guideline/amr-guidance/. Accessed 17/09/2021.
- 464 3. Thomas CM. Paradigms of plasmid organization. Mol Microbiol **2000**; 37(3): 485-91.
- 465 4. Li X, Wang Y, Brown CJ, et al. Diversification of broad host range plasmids correlates
 466 with the presence of antibiotic resistance genes. FEMS microbiology ecology 2016;
 467 92(1).
- 468 5. Matsumura Y, Peirano G, Motyl MR, et al. Global Molecular Epidemiology of IMP469 Producing Enterobacteriaceae. Antimicrobial agents and chemotherapy 2017; 61(4).
- 470 6. Macesic N, Hawkey J, Vezina B, et al. Genomic dissection of endemic carbapenem
 471 resistance reveals metallo-beta-lactamase dissemination through clonal, plasmid and
 472 integron transfer. Nature Communications 2023; 14(1): 4764.
- 473 7. England PH. Quarterly laboratory surveillance of acquired carbapenemase-producing
 474 Gram-negative bacteria in England: April 2021 to June 2021 update. Vol. 15: Assets
 475 publishing service UK government, 2021:1-14.
- 476 8. Ling Z, Yin W, Shen Z, Wang Y, Shen J, Walsh TR. Epidemiology of mobile colistin
 477 resistance genes mcr-1 to mcr-9. Journal of Antimicrobial Chemotherapy 2020; 75(11):
 478 3087-95.
- 479 9. Hussein NH, Al-Kadmy IMS, Taha BM, Hussein JD. Mobilized colistin resistance (mcr)
 480 genes from 1 to 10: a comprehensive review. Mol Biol Rep 2021; 48(3): 2897-907.
- 10. Carroll LM, Gaballa A, Guldimann C, Sullivan G, Henderson LO, Wiedmann M.
 Identification of Novel Mobilized Colistin Resistance Gene mcr-9 in a MultidrugResistant, Colistin-Susceptible Salmonella enterica Serotype Typhimurium Isolate. mBio
 2019; 10(3).
- 485 11. Kananizadeh P, Oshiro S, Watanabe S, et al. Emergence of carbapenem-resistant and
 486 colistin-susceptible Enterobacter cloacae complex co-harboring blaIMP-1 and mcr-9 in
 487 Japan.

- 488 12. Li Y, Dai X, Zeng J, Gao Y, Zhang Z, Zhang L. Characterization of the global
 489 distribution and diversified plasmid reservoirs of the colistin resistance gene mcr-9.
 490 Scientific reports 2020; 10(1): 8113.
- 491 13. Roberts LW, Catchpoole E, Jennison AV, et al. Genomic analysis of carbapenemase492 producing Enterobacteriaceae in Queensland reveals widespread transmission of bla
 493 (IMP-4) on an IncHI2 plasmid. Microbial genomics 2020; 6(1).
- 494 14. Macesic N, Blakeway LV, Stewart JD, et al. Silent spread of mobile colistin resistance
 495 gene mcr-9.1 on IncHI2 'superplasmids' in clinical carbapenem-resistant
 496 Enterobacterales. Clinical Microbiology and Infection 2021.
- 497 15. Meyers L. Contact network epidemiology: Bond percolation applied to infectious disease
 498 prediction and control. Bulletin of the American Mathematical Society 2006; 44: 63-86.
- 499 16. Newman MEJ. The Structure and Function of Complex Networks. SIAM Review 2003;
 500 45(2): 167-256.
- 501 17. Pastor-Satorras R, Castellano C, Van Mieghem P, Vespignani A. Epidemic processes in
 502 complex networks. Reviews of Modern Physics 2015; 87(3): 925-79.
- 503 18. Newman MEJ. Spread of epidemic disease on networks. Physical Review E 2002; 66(1):
 504 016128.
- 505 19. Brockmann D, Helbing D. The Hidden Geometry of Complex, Network-Driven
 506 Contagion Phenomena. Science 2013; 342(6164): 1337-42.
- 507 20. Kwong JC, Lane CR, Romanes F, et al. Translating genomics into practice for real-time
 508 surveillance and response to carbapenemase-producing Enterobacteriaceae: evidence
 509 from a complex multi-institutional KPC outbreak. PeerJ 2018; 6: e4210-e.
- 510 21. Gouliouris T, Coll F, Ludden C, et al. Quantifying acquisition and transmission of
 511 Enterococcus faecium using genomic surveillance. Nature Microbiology 2021; 6(1): 103512 11.
- 513 22. Otter JA, Mookerjee S, Davies F, et al. Detecting carbapenemase-producing
 514 Enterobacterales (CPE): an evaluation of an enhanced CPE infection control and
 515 screening programme in acute care. Journal of Antimicrobial Chemotherapy 2020; 75(9):
 516 2670-6.
- 517 23. EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1.
 518 European Committee on Antimicrobial Susceptibility Testing 2017.

- 519 24. Jain C, Rodriguez-R LM, Phillippy AM, Konstantinidis KT, Aluru S. High throughput
 520 ANI analysis of 90K prokaryotic genomes reveals clear species boundaries. Nature
 521 Communications 2018; 9(1): 5114.
- 522 25. Robertson J, Nash JHE. MOB-suite: software tools for clustering, reconstruction and
 523 typing of plasmids from draft assemblies. Microbial genomics **2018**; 4(8).
- 524 26. Minh BQ, Schmidt HA, Chernomor O, et al. IQ-TREE 2: New Models and Efficient
 525 Methods for Phylogenetic Inference in the Genomic Era. Mol Biol Evol 2020; 37(5):
 526 1530-4.
- 527 27. Croucher NJ, Page AJ, Connor TR, et al. Rapid phylogenetic analysis of large samples of
 528 recombinant bacterial whole genome sequences using Gubbins. Nucleic Acids Res 2015;
 529 43(3): e15.
- 530 28. Didelot X, Croucher NJ, Bentley SD, Harris SR, Wilson DJ. Bayesian inference of
 531 ancestral dates on bacterial phylogenetic trees. Nucleic Acids Research 2018; 46(22):
 532 e134-e.
- 29. Pons P, Latapy M. Computing Communities in Large Networks Using Random Walks.
 Berlin, Heidelberg: Springer Berlin Heidelberg, 2005:284-93.
- 535 30. Landman D, Salamera J, Quale J. Irreproducible and uninterpretable Polymyxin B MICs
 536 for Enterobacter cloacae and Enterobacter aerogenes. Journal of clinical microbiology
 537 2013; 51(12): 4106-11.
- 538 31. Fournier S, Desenfant L, Monteil C, et al. Efficiency of different control measures for
 539 preventing carbapenemase-producing enterobacteria and glycopeptide-resistant
 540 Enterococcus faecium outbreaks: a 6-year prospective study in a French multihospital
 541 institution, January 2010 to December 2015. Euro Surveill 2018; 23(8): 17-00078.
- 542 32. Turton J, Davies F, Taori S, Smith SL, Sajedi N, Wootton M. IncN3 and IncHI2
 543 plasmids with an In1763 integron carrying bla IMP-1 in carbapenem-resistant
 544 Enterobacterales clinical isolates from the UK. Journal of medical microbiology 2020.
- 545 33. Kieffer N, Royer G, Decousser JW, et al. mcr-9, an Inducible Gene Encoding an
 546 Acquired Phosphoethanolamine Transferase in Escherichia coli, and Its Origin.
 547 Antimicrobial agents and chemotherapy 2019; 63(9).
- 548 34. Otter JA, Doumith M, Davies F, et al. Emergence and clonal spread of colistin resistance
 549 due to multiple mutational mechanisms in carbapenemase-producing Klebsiella
 550 pneumoniae in London. Scientific reports 2017; 7(1): 12711.

- 35. Otter JA, Mutters NT, Tacconelli E, Gikas A, Holmes AH. Controversies in guidelines
 for the control of multidrug-resistant Gram-negative bacteria in EU countries. Clinical
 microbiology and infection : the official publication of the European Society of Clinical
 Microbiology and Infectious Diseases 2015; 21(12): 1057-66.
- 36. Jamal AJ, Garcia-Jeldes F, Baqi M, et al. Infection prevention and control practices
 related to carbapenemase-producing Enterobacteriaceae (CPE) in acute-care hospitals in
 Ontario, Canada. Infection Control & Hospital Epidemiology 2019; 40(9): 1006-12.
- 37. Harris AD, McGregor JC, Furuno JP. What Infection Control Interventions Should Be
 Undertaken to Control Multidrug-Resistant Gram-Negative Bacteria? Clinical Infectious
 Diseases 2006; 43(Supplement_2): S57-S61.
- 561 38. Doron S, Davidson LE. Antimicrobial stewardship. Mayo Clin Proc 2011; 86(11): 1113-
- 562 23.
- 563